文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

艾巴利珠单抗联合来那卡帕韦治疗多重耐药HIV-1的病例系列

Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series.
PubMed 文献 · Clin Infect Dis · 2026-01-01

该回顾性观察研究分析了美国8家机构21例多重耐药HIV-1感染者的病历,所有患者均接受艾巴利珠单抗联合来那卡帕韦(联合或不联合优化背景方案)至少6个月。治疗12至24周内HIV RNA中位下降2710拷贝/mL,CD4+计数中位增加67.5个/mm3,耐受性良好。

要点

  • 艾巴利珠单抗联合来那卡帕韦可使多重耐药HIV-1患者病毒载量中位下降2710拷贝/mL。
  • 治疗4至44周内CD4+计数中位增加67.5个/mm3,耐受性良好。
  • 该联合方案为治疗经历复杂或依从性困难的多重耐药HIV患者提供了 salvage 治疗选择。

核心结论

  • 在高度治疗经历和/或面临依从性挑战的多重耐药HIV-1感染者中,艾巴利珠单抗联合来那卡帕韦(联合或不联合优化背景方案)耐受性良好,并带来临床显著的病毒载量下降和CD4+计数改善。

研究设计与样本

  • 回顾性观察研究,纳入美国8家机构21例多重耐药HIV-1感染者,所有患者接受艾巴利珠单抗联合来那卡帕韦(联合或不联合优化背景方案)至少6个月。

主要发现

  • 基线时38.1%的患者报告四类耐药。
  • 治疗12至24周内HIV RNA中位下降2710拷贝/mL。
  • 治疗4至44周内CD4+计数中位增加67.5个/mm3。
  • 因不耐受需调整治疗的情况较少。
  • 艾巴利珠单抗和来那卡帕韦的平均持续使用时间分别为30个月和20个月。

临床怎么用

  • 对于治疗选择有限的多重耐药HIV-1感染者,可考虑艾巴利珠单抗联合来那卡帕韦(联合或不联合优化背景方案)作为挽救治疗方案。

局限性

  • 样本量小(21例),为回顾性观察研究,证据等级有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Some individuals with human immunodeficiency virus (HIV-1) have acquired multidrug-resistant (MDR) strains of HIV and/or are nonadherent to antiretroviral (ARV) medication. Injectable ARVs can provide salvage therapy for those with limited therapeutic options and may be preferred by some people with HIV (PWH). Real-world evidence may contribute to a more comprehensive understanding of the barriers to adherence and the utility of injectable ARVs in PWH. Currently, there is a lack of data on combined use of injectable ibalizumab (IBA) and lenacapavir (LEN) with optimized background regimen (OBR). METHODS: A retrospective observational study examined medical charts from people with MDR HIV across 8 facilities in the United States. All PWH used a combination of both IBA + LEN ± OBR for at least 6 months. Viral loads and CD4+ counts were collected. RESULTS: A total of 21 PWH were included. Four-class resistance at baseline was reported in 38.1% of PWH. Within 12 to 24 weeks of combined IBA + LEN treatment, a median reduction of -2710 copies/mL HIV RNA was observed. Median increase to CD4+ count was 67.5 cells/mm3 within 4 to 44 weeks of treatment initiation. Few intolerances required changes to treatment. Therapy with IBA + LEN continued for an average of 30 months and 20 months, respectively. CONCLUSIONS: In this small group of individuals with MDR HIV who were heavily treatment-experienced and/or faced adherence challenges, the use of IBA + LEN ± OBR was well tolerated and led to clinically significant reductions in viral loads and improvements in CD4+ counts.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Rolle C, Achhra A, Harbison C, et al. Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series. Clin Infect Dis. 2026. PMID: 41187020. doi:10.1093/cid/ciaf597

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。